Aegle Therapeutics Corporation, an Arlington and Miami-based biotechnology company developing extracellular vesicles as therapy, completed a $6.5M Series A round of financing.
Investors included Tellus BioVentures, New World Angels, DEFTA Healthcare Technologies and DeepWork Capital.
Led by Shelley Hartman, Chief Executive Officer, Aegle Therapeutics is a biotechnology company developing extracellular vesicles, including exosomes, secreted by mesenchymal stem cells as therapy for the treatment of dystrophic epidermolysis bullosa and other severe dermatological conditions. The company anticipates entering the clinic with AGLE-102 in early 2021.
Aegle has also announced the appointment of Heidi Kempinski as Senior Vice President, Head of Operations. Kempinski brings over 25 years’ experience in global drug development to Aegle, most recently at GSK where she served as VP of Business Operations and Strategic Alliances. Prior to GSK, Kempinski was a member of the initial management team at TESARO, Inc., where she established and managed R&D and Technical Operations.